Results 231 to 240 of about 86,601 (293)

Phase 1 Dose Escalation of Single‐Agent Mechlorethamine in Dogs With Lymphoma

open access: yesVeterinary and Comparative Oncology, Volume 24, Issue 1, Page 51-57, March 2026.
ABSTRACT Mechlorethamine is commonly prescribed to dogs at 3 mg/m2. The minimal toxicity observed indicates that higher doses of mechlorethamine are likely tolerable. The primary objective of this study was to determine the maximally tolerated dose (MTD) of mechlorethamine in dogs with lymphoma.
Laura E. Chadsey   +2 more
wiley   +1 more source

Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.

open access: yesBlood
Sam J   +23 more
europepmc   +1 more source

Economic burden and quality of life caused by non-hodgkin lymphoma cancer in Iran. [PDF]

open access: yesJ Health Popul Nutr
Ghiasi M   +9 more
europepmc   +1 more source

A Comparative Study of Melanocytic Tumours: Linking Portuguese Dogs and Cats to Human Cases

open access: yesVeterinary and Comparative Oncology, Volume 24, Issue 1, Page 105-120, March 2026.
ABSTRACT Melanocytic tumours (MT) occur in both humans and companion animals, presenting an opportunity for comparative oncology research. Thus, this study provides a comprehensive epidemiological analysis comparing MT in Portuguese dogs, cats and humans. Data were obtained from the Portuguese National Cancer Registry (RON) (2011–2021) and Vet‐OncoNet (
Catarina Alves Pinto   +5 more
wiley   +1 more source

Over one‐third of cancer cases and two‐fifths of cancer deaths in southern China are preventable: Insights from the latest representative population‐based cancer registry data and risk factor survey

open access: yesInternational Journal of Cancer, Volume 158, Issue 4, Page 909-923, 15 February 2026.
What's new? This study quantified the cancer burden attributable to modifiable risk factors in Guangdong, the most populous and economically advanced province in southern China. By evaluating 15 modifiable risk factors, the study reveals that over one‐third of cancer cases and two‐fifths of cancer deaths in the region could potentially be prevented ...
Xiaolan Wen   +17 more
wiley   +1 more source

Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma. [PDF]

open access: yesClin Cancer Res
Hijazi A   +6 more
europepmc   +1 more source

Safety and Efficacy of Anticoagulation Therapy in Paediatric Patients With Solid Tumours or Lymphomas at Risk of Thrombocytopenia: A Retrospective Study

open access: yesPediatric Blood &Cancer, Volume 73, Issue 2, February 2026.
ABSTRACT Background Patients with solid tumours or lymphomas have an increased risk of thromboembolism (TE) and thrombocytopenia. Evidence‐based strategies for anticoagulation therapy (ACT) for patients with thrombocytopenia are limited. We examined the impact of thrombocytopenia on ACT administration and bleeding incidence in children with solid ...
Andrés Felipe Fajardo   +5 more
wiley   +1 more source

Trends of Non-Hodgkin Lymphoma Incidence Among Adults in the United States From 2000 to 2020. [PDF]

open access: yesCancer Rep (Hoboken)
Aslani A   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy